Seattle Genetics appoints new Chief Commercial Officer

May 21, 2019 Off By BusinessWire

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of
Robin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer. Dr. Taylor
brings 18 years of biotechnology and pharmaceutical company experience
in the commercialization of oncology drugs, including significant
marketing, launch and global product strategy roles at both
Genentech/Roche and AstraZeneca. He contributed to several leading
global brands, including TECENTRIQ^® (atezolizumab), ALECENSA^®
(alectinib), AVASTIN^® (bevacizumab) and HERCEPTIN^®
(trastuzumab).

Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle
Genetics, commented, “We are excited to welcome Robin to the executive
management team as our first Chief Commercial Officer. He has
demonstrated strong leadership and success in the global commercial
development and strategic marketing of several oncology franchises,
notably at Genentech/Roche. Robin will play a key role in extending our
commercial execution across six ADCETRIS lymphoma indications, while
preparing for the potential launch of enfortumab vedotin and leading our
global commercialization strategy for possible future products, such as
tucatinib.”

Dr. Taylor stated, “Seattle Genetics has an outstanding culture of
innovation and scientific excellence with a broad late-stage pipeline
focused on providing a significant benefit to cancer patients with high
unmet need. I look forward to leading the Commercial organization to
bring these exciting therapies to patients as the company transitions to
a multi-product, global oncology company.”

Robin Taylor has extensive global development and commercialization
oncology experience. Most recently, he served as Vice President,
Immuno-Oncology Franchise Head, Oncology Business Unit at AstraZeneca,
where he led global marketing and product teams for IMFINZI^®
(durvalumab), an immunotherapy approved for metastatic urothelial
carcinoma, and Stage III unresectable non-small cell lung cancer. Prior
to joining AstraZeneca, Dr. Taylor served in roles of increasing
responsibility at Genentech, a Member of the Roche Group, from 2001 to
2018. Most recently, he served as Vice President, Cancer Immunotherapy
Franchise Head, Global Product Strategy, responsible for the global
development and launch of TECENTRIQ across multiple indications. He
received a Doctor of Philosophy, Molecular and Medical Genetics from
University of Toronto, a Masters of Business Administration from
University of California Berkeley, and a Bachelor of Science degree from
University of British Columbia.

About Seattle Genetics

Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes transformative
therapies targeting cancer to make a meaningful difference in people’s
lives. ADCETRIS^® (brentuximab vedotin) utilizes the company’s
industry-leading ADC technology and is currently approved for the
treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the
company has established a pipeline of novel targeted therapies at
various stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic urothelial
cancer and tisotumab vedotin for metastatic cervical cancer utilize our
proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase
inhibitor, is in a pivotal trial for HER2-positive metastatic breast
cancer. In addition, we are leveraging our expertise in empowered
antibodies to build a portfolio of proprietary immuno-oncology agents in
clinical trials targeting hematologic malignancies and solid tumors. The
company is headquartered in Bothell, Washington, and has a European
office in Switzerland. For more information on our robust pipeline,
visit www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company’s
transition into a multi-product global oncology company, expectations
regarding expansion of the commercial uses of ADCETRIS and advancement
of the company’s late-stage oncology pipeline, including enfortumab
vedotin, tisotumab vedotin and tucatinib and the company’s other product
candidates and those of its licensees and collaborators; as well as
other statements that are not historical facts. Actual results or
developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with
maintaining or increasing sales of ADCETRIS due to competition,
unexpected adverse events, regulatory action, reimbursement, market
adoption by physicians or other factors. The company may also be delayed
in its planned clinical trial initiations, the enrollment in and conduct
of its clinical trials, obtaining data from clinical trials, planned
regulatory submissions, and regulatory approvals in each case for a
variety of reasons including the difficulty and uncertainty of
pharmaceutical product development, negative or disappointing clinical
trial results, unexpected adverse events or regulatory discussions or
actions and the inherent uncertainty associated with the regulatory
approval process. More information about the risks and uncertainties
faced by Seattle Genetics is contained under the caption “Risk Factors”
in the Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2019 filed with the Securities and Exchange
Commission. Seattle Genetics disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise except as required by
applicable law.